AFT chairman defends preference share issue
Controlling shareholders get dividend-paying stock in $9.1 million capital raise.
AFT Pharmaceuticals chairman David Flacks is defending a hybrid share issue to company insiders that pays a 9.4% dividend, saying the deal is “the best of all worlds for us.”
The maker of healthcare products such as Maxigesic, a paracetamol ibuprofen combo, said on Friday it would raise $9.1
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Tim Hunter
Tue, 21 Mar 2017
Tue, 21 Mar 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
AFT chairman defends preference share issue
65715